All In Biotech

Drug Trial Radar · NCT04963296

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 303 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

303

Actual

Start

Oct 26, 2021

Primary completion

Sep 15, 2025

Study completion Mar 13, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • ObinutuzumabDrug

    Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.

  • PlaceboDrug

    Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.

  • Acetaminophen/ParacetamolDrug

    Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

  • Diphenhydramine hydrochlorideDrug

    Diphenhydramine 50 mg will be administered as premedication prior to infusions.

  • MethylprednisoloneDrug

    Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52Time frame: At Week 52

Locations

63 sites in 14 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • Unity Health - White County Medical Center- Rheumatology

    Searcy, Arkansas

  • Providence Medical Foundation

    Fullerton, California

  • Arthritis & Rheumatism

    Aventura, Florida

  • Great Lakes Center of Rheumatology

    Lansing, Michigan

  • Clinical Research Institute of Michigan, LLC

    Troy, Michigan

  • Northwell Health Division of Rheumatology

    Great Neck, New York

  • Columbia University Medical Center

    New York, New York

  • Joint & Muscle Research Institute

    Charlotte, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, Ohio

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas

  • Texas Arthritis Center

    El Paso, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Organizacion Medica de Investigacion

    Buenos Aires, Argentina

  • DOM Centro de Reumatología

    Buenos Aires, Argentina

  • Centro de Investigaciones Médicas Tucuman

    San Miguel, Argentina

  • Ser Servicos Especializados Em Reumatologia

    Salvador, Estado de Bahia, Brazil

  • Hospital das Clinicas - UFMG

    Belo Horizonte, Minas Gerais, Brazil

  • Santa Casa de Misericordia

    Belo Horizonte, Minas Gerais, Brazil

  • Centro Mineiro de Pesquisa - CMIP

    Juiz de Fora, Minas Gerais, Brazil

  • Centro de Estudos em Terapias Inovadoras ? CETI

    Curtiba, Paraná, Brazil

  • Hospital das Clinicas - FMUSP Ribeirao Preto

    Ribeirão Preto, São Paulo, Brazil

  • Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*

    São Bernardo do Campo, São Paulo, Brazil

  • Revmatologicky Ustav

    Prague, Czechia

  • Ch Pitie Salpetriere

    Paris, France

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, Italy

  • IRCCS S. Raffaele

    Milan, Lombardy, Italy

  • A.O. Universitaria Pisana

    Pisa, Tuscany, Italy

  • Azienda Ospedaliero-Universitaria Di Ferrara Arcispedale Santanna

    Cona (Ferrara), Veneto, Italy

  • Uni Di Padova

    Padova, Veneto, Italy

  • Centro de Investigacion Alberto Bazzoni S.A. de C.V.

    Torreón, Coahuila, Mexico

  • Unidad de Reumatologia Rehabilitacion Integral

    Mexicali, Estado de Baja California, Mexico

  • Centro de Investigación y Tratamiento Reumatológico S.C.

    Mexico City, Mexico CITY (federal District), Mexico

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, Mexico

  • Middlemore Hospital

    Auckland, New Zealand

  • Wellington Hospital

    Wellington, New Zealand

  • Hogar Clínica San Juan de Dios

    Arequipa, Peru

  • Clínica San Juan Bautista CSJB

    Lima, Peru

  • Instituto de Ginecología y Reproducción

    Lima, Peru

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.